<DOC>
	<DOCNO>NCT02344901</DOCNO>
	<brief_summary>The aim study evaluate present status stroke prevention strategy patient non-valvular atrial fibrillation ( NVAF ) . Vitamin K antagonist ( VKAs ) available oral anticoagulant therapy decade . Recently novel oral anticoagulant emerge alternative VKAs . This study plan evaluate epidemiological characteristic , thromboembolic bleeding risk , stroke prevention strategy appropriateness oral anticoagulant use NVAF patient . Time therapeutic range ( TTR ) go calculate percent visit range ( 2-3 ) warfarin patient . This national multicenter observational study Turkey divide seven region . A proportional number patient population every region plan include .</brief_summary>
	<brief_title>ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies ( RAMSES )</brief_title>
	<detailed_description>Atrial fibrillation ( AF ) , classify nonvalvular ( NVAF ) absence rheumatic mitral stenosis valvular prosthesis , common arrhythmia , estimate prevalence 1.5-2 % . AF associate great risk arterial thromboembolic event , especially cerebrovascular , whose incidence 5-7 time higher . The risk death also double , AF great degree disability probability recurrence stroke due cause . To prevent stroke patient NVAF , antithrombotic treatment employ oral anticoagulant vitamin K antagonist ( VKA ) , number circumstance , antiplatelet agent . Although VKA ( mainly warfarin ) highly effective reduce risk stroke , sole choice stroke prevention last 50 year , use limit number reason : narrow therapeutic range , drug food interaction , need monitoring , risk bleeding . Recently , new oral anticoagulant ( NOACs ) market indication . The aim study determine standard clinical practice follow treatment prevent stroke patient NVAF Turkey . The purpose study demonstrate current status clinical background AF patient follow , analyze evaluate patient AF large multicenter nation-wide trial . The primary inclusion criterion age â‰¥18 year electrocardiographically confirm NVAF ( eg , electrocardiogram , Holter monitoring , etc ) . The enrollment patient start February 2014 . All participate institution enroll consecutive patient NVAF regular outpatient care admission .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<criteria>Atrial fibrillation Valvular heart disease ( mitral stenosis , prosthetic heart valve , heart valve surgery )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>non-valvular atrial fibrillation</keyword>
	<keyword>stroke prevention</keyword>
	<keyword>novel oral anticoagulant</keyword>
	<keyword>warfarin</keyword>
</DOC>